View in EDS

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

Saved in:
Bibliographic Details
Title: Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Authors: Gettinger, Scott N1 scott.gettinger@yale.edu, Bazhenova, Lyudmila A2, Langer, Corey J3, Salgia, Ravi4, Gold, Kathryn A2, Rosell, Rafael5, Shaw, Alice T6, Weiss, Glen J7, Tugnait, Meera8, Narasimhan, Narayana I8, Dorer, David J8, Kerstein, David8, Rivera, Victor M8, Clackson, Timothy8, Haluska, Frank G8, Camidge, David Ross9
Source: Lancet Oncology. Dec2016, Vol. 17 Issue 12, p1683-1696. 14p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(16)30392-8